Prevention of epileptogenesis - are we there yet?
| Autor: | Koepp M; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology.; National Hospital for Neurology and Neurosurgery, London, UK., Trinka E; Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian-Doppler University Hospital, Paracelsus Medical University, Centre for Cognitive Neuroscience, Member of EpiCARE.; Neuroscience Institute, Christian-Doppler University Hospital, Paracelsus Medical University, Centre for Cognitive Neuroscience, Salzburg, Austria., Löscher W; Translational Neuropharmacology Lab, NIFE, Department of Experimental Otology of the ENT Clinics, Hannover Medical School.; Center for Systems Neuroscience, Hannover, Germany., Klein P; Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in neurology [Curr Opin Neurol] 2024 Feb 13. Date of Electronic Publication: 2024 Feb 13. |
| DOI: | 10.1097/WCO.0000000000001256 |
| Abstrakt: | Purpose of Review: To review recent progress in preventing epileptogenesis in patients with epilepsy. Recent Findings: The recent success of epilepsy prevention and disease modification in tuberous sclerosis using simple EEG biomarkers to guide treatment initiation, and the identification of biomarkers to enrich the targeted patient population has made clinical trials of epilepsy prevention after acquired central nervous system (CNS) insults such as traumatic brain injury, stroke or infection both feasible and timely. Two such trials are currently on-going to prevent poststroke epilepsy. Summary: No disease-modifying or preventive treatments exist for epilepsy, and their development remains a major unmet need.. We have entered though the era of change in the treatment of epilepsy from symptomatic only to disease prevention. In this review, we summarize developments and review opportunities, challenges, and potential solutions to develop preventive treatment for acquired epilepsies in humans. The 'Holy Grail' of epilepsy is within our reach. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|